{"id":2400,"date":"2007-07-03T19:52:21","date_gmt":"2007-07-03T18:52:21","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2400"},"modified":"2013-09-20T16:09:09","modified_gmt":"2013-09-20T16:09:09","slug":"scherings-pegylated-interferon-approved-for-treating-hepatitis-c-in-hiv-coinfected-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2400","title":{"rendered":"Schering\u0092s pegylated interferon approved for treating hepatitis C in HIV coinfected patients"},"content":{"rendered":"<p><strong>On 25 June 25, 2007, Schering-Plough announced that the European Commission has approved combination therapy with Pegintron (peginterferon alfa-2b, 1.5 mcg\/kg once weekly) and Rebetol (ribavirin, 800 \u0096 1,200 mg daily) for the treatment of previously untreated adult patients with chronic hepatitis C who are coinfected with clinically stable HIV.<\/strong><\/p>\n<p>The European Commission approval results in Marketing Authorization with unified labeling that is valid in the current European Union (EU) 27 member states as well as in Iceland and Norway.<\/p>\n<p>Although already widely used in coinfected patients earlier EU approval in March 2001 was for treating adult patients with chronic hepatitis C alone.<\/p>\n<p>Approval was based on the results of two published clinical studies in previously HCV untreated adult patients. [1, 2] Duration of treatment in HCV\/HIV coinfected patients is 48 weeks, regardless of HCV genotype.<\/p>\n<h3 class=\"comment\">Comment<\/h3>\n<p class=\"comment\"><strong>For approval in coinfected patients to come more than 5 years after the original indication highlights the delay that coinfected patients face in access to new treatments for hepatitis C, which was recognised in a recent EU concept paper. <\/strong>[3]<\/p>\n<p>Source: Schering-Plough press release (06\/25\/07).<br \/>\n<a href=\"http:\/\/www.schering-plough.com\">http:\/\/www.schering-plough.com<\/a><\/p>\n<p class=\"ref\">References:<\/p>\n<ol>\n<li>Carrat F, Bani-Sadir F, Pol S et al. JAMA 2004; 292(23): 2839-2848.<\/li>\n<li>Laguno M, Murillas J, Blanco J et al. AIDS 2004; 18(13): F27-F36.<\/li>\n<li>Concept paper for clinical development of medicinal products for the treatment of hepatitis C infection (26 April). Ref: EMEA\/CHMP\/EWP\/156308\/2007<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>On 25 June 25, 2007, Schering-Plough announced that the European Commission has approved combination therapy with Pegintron (peginterferon alfa-2b, 1.5 mcg\/kg once weekly) and Rebetol (ribavirin, 800 \u0096 1,200 mg daily) for the treatment of previously untreated adult patients with &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[],"class_list":["post-2400","post","type-post","status-publish","format-standard","hentry","category-hepatitis-coinfection"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2400"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2400\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}